spi-62
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 5, 2021 (NCT05409027)
Timeline
Indications
Mechanism of action
- 11-beta-hydroxysteroid dehydrogenase 1ANTAGONIST
HSD11B1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(-c2ccc(C(N)=O)cc2F)nnc1C(C)(C)Oc1c(F)cc(Cl)cc1F- Mol. weight
- 424.81 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314513 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07296484 | Phase 2 | Dec 31, 2025 | Sparrow Pharmaceuticals |
| NCT07227922 | Phase 1 | Nov 30, 2025 | Sparrow Pharmaceuticals |
| NCT07226635 | Phase 1 | Oct 3, 2025 | Sparrow Pharmaceuticals |
| NCT06281236 | Phase 1 | Feb 22, 2024 | Sparrow Pharmaceuticals |
| NCT05436652 | Phase 2 | Jul 22, 2022 | Sparrow Pharmaceuticals |
| NCT05436639 | Phase 2 | Jun 9, 2022 | Sparrow Pharmaceuticals |
| NCT05307328 | Phase 2 | Mar 1, 2022 | Sparrow Pharmaceuticals |
| NCT05409027 | Phase 1 | Aug 5, 2021 | Sparrow Pharmaceuticals |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sparrow Pharmaceuticals | For profit | 8 | 8 | 2 | 2021 |
1 organizations
Page 1 / 1